AU2017363307B2 - Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof - Google Patents

Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof Download PDF

Info

Publication number
AU2017363307B2
AU2017363307B2 AU2017363307A AU2017363307A AU2017363307B2 AU 2017363307 B2 AU2017363307 B2 AU 2017363307B2 AU 2017363307 A AU2017363307 A AU 2017363307A AU 2017363307 A AU2017363307 A AU 2017363307A AU 2017363307 B2 AU2017363307 B2 AU 2017363307B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
certain embodiments
carbocyclyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017363307A
Other languages
English (en)
Other versions
AU2017363307A1 (en
Inventor
Nathanael S. Gray
Baishan JIANG
Nicholas Paul Kwiatkowski
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2017363307A1 publication Critical patent/AU2017363307A1/en
Application granted granted Critical
Publication of AU2017363307B2 publication Critical patent/AU2017363307B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017363307A 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof Active AU2017363307B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425519P 2016-11-22 2016-11-22
US62/425,519 2016-11-22
PCT/US2017/063132 WO2018098361A1 (en) 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof

Publications (2)

Publication Number Publication Date
AU2017363307A1 AU2017363307A1 (en) 2019-05-02
AU2017363307B2 true AU2017363307B2 (en) 2021-07-29

Family

ID=60703092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017363307A Active AU2017363307B2 (en) 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof

Country Status (6)

Country Link
US (2) US11306070B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544971B1 (cg-RX-API-DMAC7.html)
JP (1) JP7258748B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017363307B2 (cg-RX-API-DMAC7.html)
CA (1) CA3041563C (cg-RX-API-DMAC7.html)
WO (1) WO2018098361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
AU2019291935A1 (en) * 2018-06-29 2021-02-04 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用
CA3124422A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020219650A1 (en) * 2019-04-23 2020-10-29 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
WO2020219926A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
CA3156610A1 (en) * 2019-10-29 2021-05-06 J. Graeme HODGSON Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
CN111269217B (zh) * 2020-04-07 2021-01-08 苏州信诺维医药科技有限公司 一种嘧啶胺类化合物、其制备方法及应用
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
WO2022046999A1 (en) * 2020-08-26 2022-03-03 Massachusetts Institute Of Technology Modulators of myb-mediated transcription and uses thereof
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
CA3228553A1 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
WO2023091726A1 (en) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin‑dependent kinase 12 (cdk12)
WO2023102184A1 (en) * 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
KR102821060B1 (ko) 2023-03-09 2025-06-16 미네암리타 테라퓨틱스, 엘엘씨 위암의 치료를 위한 약물 조합

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058140A1 (en) * 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015154038A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) * 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
US7074800B1 (en) 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
AU6605200A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
ES2365245T3 (es) 2005-01-10 2011-09-27 Pfizer, Inc. Pirrolopirazoles, potentes inhibidores de quinasas.
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
AU2009227013B2 (en) 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
JP2012511021A (ja) 2008-12-05 2012-05-17 アークル インコーポレイテッド Ｒａｆの阻害剤およびその使用
CN102317282A (zh) 2009-02-12 2012-01-11 安斯泰来制药有限公司 杂环衍生物
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
CN103313987A (zh) 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
EP3057954A2 (en) * 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
CA3043222A1 (en) 2016-11-28 2018-05-31 Dana-Farber Cancer Institute, Inc. Reagents and methods for analysis of proteins and metabolites targeted by covalent probes
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7642540B2 (ja) * 2018-12-14 2025-03-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用
CA3124422A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3166135A1 (en) * 2019-12-24 2021-07-01 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058140A1 (en) * 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015154038A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) * 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
CA3041563A1 (en) 2018-05-31
WO2018098361A1 (en) 2018-05-31
EP3544971B1 (en) 2022-07-06
AU2017363307A1 (en) 2019-05-02
US20220213067A1 (en) 2022-07-07
JP2019535749A (ja) 2019-12-12
JP7258748B2 (ja) 2023-04-17
CA3041563C (en) 2023-10-31
US20230227433A9 (en) 2023-07-20
US11932625B2 (en) 2024-03-19
EP3544971A1 (en) 2019-10-02
US20200361906A1 (en) 2020-11-19
US11306070B2 (en) 2022-04-19
US20210317105A9 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
AU2017363313B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
AU2016319125B2 (en) Inhibitors of cyclin-dependent kinases
AU2016283105C1 (en) 4,6-pyrimidinylene derivatives and uses thereof
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
AU2020301399B2 (en) HCK degraders and uses thereof
CA3132387A1 (en) Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
EP3877371A1 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
EP3313529A1 (en) Fused bicyclic pyrimidine derivatives and uses thereof
WO2020097396A1 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
CA3106548A1 (en) Histone demethylase 5 inhibitors and uses thereof
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)